Medical Device Nonvisual Accessibility Act of 2025

The Medical Device Nonvisual Accessibility Act of 2025 amends the Federal Food, Drug, and Cosmetic Act to establish nonvisual accessibility standards for medical devices with digital interfaces. This means all new and existing medical devices with digital screens must incorporate features like text-to-speech software or other nonvisual access technologies. This is a direct mandate, not a suggestion, and creates a new, non-negotiable compliance requirement for all medical device manufacturers. The bill is currently in the House and has 17 cosponsors, indicating moderate legislative momentum. The money trail for this legislation flows directly into research, development, and implementation of accessibility features. Medical device companies will allocate capital to redesign existing products and integrate accessibility from the start for new products. This creates a new market for specialized accessibility technology providers. Companies like NVIDIA ($NVDA) and Microsoft ($MSFT), which develop AI and text-to-speech technologies, stand to gain as their platforms and tools become essential for compliance. Google ($GOOGL) also benefits from increased demand for its accessibility APIs and software development kits. Medical device companies like Medtronic ($MDT), Intuitive Surgical ($ISRG), Abbott Laboratories ($ABT), Tandem Diabetes Care ($TNDM), and Dexcom ($DXCM) will incur initial development costs but will expand their total addressable market by making their devices usable by blind and low-vision individuals. Historically, similar accessibility mandates have driven innovation and market expansion. For example, the Americans with Disabilities Act (ADA) of 1990, while broader, led to widespread adoption of accessibility features across various industries. While direct market data for medical device-specific accessibility mandates is limited, the Section 508 amendment to the Rehabilitation Act in 1998, which mandated electronic and information technology accessibility for federal agencies, created a significant market for accessibility software and services. Companies specializing in assistive technology saw sustained growth following its implementation. This bill is expected to have a similar, albeit more focused, effect on the medical device sector. Specific winners include companies providing core accessibility technologies: NVIDIA ($NVDA) for AI and speech processing, Microsoft ($MSFT) for operating system-level accessibility tools, and Google ($GOOGL) for its Android accessibility suite and AI capabilities. Medical device manufacturers like Medtronic ($MDT), Intuitive Surgical ($ISRG), Abbott Laboratories ($ABT), Tandem Diabetes Care ($TNDM), and Dexcom ($DXCM) are direct beneficiaries of an expanded market, despite initial compliance costs. Losers are medical device companies that fail to adapt quickly, risking market share loss and regulatory penalties. The timeline for this bill is that it was introduced on September 26, 2025, and referred to the Committee on Energy and Commerce. If it passes, manufacturers will have a compliance period, likely 1-3 years, to implement the changes. This bill does not appropriate specific dollar amounts but mandates a market shift. The increased development costs for medical device manufacturers will be offset by access to a previously underserved market segment. The bill's passage will create a new revenue stream for accessibility technology providers and a competitive advantage for medical device companies that proactively integrate these standards.